BHVN240517P55000
- 15.93
- 0.000.00%
Biohaven Newsroom
This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan
The Structure Therapeutics (NASDAQ:GPCR) stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the stock a significant upside potential.What Happened: JPMorgan
Express News | Biohaven Ltd : JP Morgan Cuts Target Price to $55 From $57
Express News | NYSE Order Imbalance 61052.0 Shares on Sell Side
Director Gregory Bailey Acquires 15,000 Shares of Biohaven Ltd (BHVN)
Biohaven(BHVN.US) Director Buys US$512.88K in Common Stock
$Biohaven(BHVN.US)$ Director Bailey Gregory purchased 15,000 shares of common stock on May 13, 2024 at an average price of $34.1918 for a total value of $512.88K.Source: Announcement What is statement
Biohaven Insider Bought Shares Worth $512,877, According to a Recent SEC Filing
Gregory Bailey, Director, on May 13, 2024, executed a purchase for 15,000 shares in Biohaven (BHVN) for $512,877. Following the Form 4 filing with the SEC, Bailey has control over a total of 1,615,071
Sony Group Posts Upbeat Earnings, Joins GameStop, Paysafe And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Dow Jones gaining around 20 points on Tuesday.Shares of Sony Group Corporation (NYSE:SONY) rose sharply during Tuesday's session after the company reported better-tha
Biohaven(BHVN.US) Director Buys US$1 Million in Common Stock
$Biohaven(BHVN.US)$ Director CHILDS JOHN W purchased 28,500 shares of common stock on May 13, 2024 at an average price of $35.1744 for a total value of $1 million.Source: Announcement What is statemen
Biohaven Insider Bought Shares Worth $1,002,470, According to a Recent SEC Filing
John W Childs, Director, on May 13, 2024, executed a purchase for 28,500 shares in Biohaven (BHVN) for $1,002,470. Following the Form 4 filing with the SEC, Childs has control over a total of 6,404,24
Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Biohaven Ltd. (BHVN) and Arrowhead Pharmaceuticals (ARWR)
Buy Rating Affirmed on Biohaven Ltd. Amidst Pipeline Potential and Upcoming Developments
Express News | NYSE Order Imbalance 56854.0 Shares on Buy Side
Down -32.76% in 4 Weeks, Here's Why Biohaven Ltd. (BHVN) Looks Ripe for a Turnaround
Crocs To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Jefferies c
Biohaven Is Maintained at Buy by HC Wainwright & Co.
Biohaven Is Maintained at Buy by HC Wainwright & Co.
Biohaven Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 65.68% HC Wainwright & Co. $63 → $59 Maintains Buy 04/23/2024 68.49% UBS $59 → $60 Maintains Bu
Express News | Biohaven Ltd. : H.c. Wainwright Cuts Target Price to $59 From $63
Express News | Biohaven Shares Are Trading Lower After the Company Reported Q1 Financial Results
Express News | Biohaven Shares Fall 8.4% After Co Reports Wider-Than-Expected Q1 Loss
Express News | Biohaven On Thursday Reported Q1 2024 Adj. EPS $(1.77) Down From $(0.98) YoY